ASX:PNV

PolyNovo (PNV) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
3.38 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
6.86%
Price Target
N/A
PNV stock logo

About PolyNovo Stock (ASX:PNV)

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

PNV Stock News Headlines

Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
PolyNovo Limited (PNV.AX)
Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?
Polynovo Ltd (MFJ.SG)
PNV.AX - PolyNovo Limited
See More Headlines
Receive PNV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyNovo and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
237
Year Founded
N/A

Profitability

Net Income
$1.59 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$83.47 million
Book Value
A$0.10 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.65
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Swami Raote BPHARM
    M.B.A., CEO & Director
  • Mr. Jan-Marcel Gielen C.A.
    CFO & Company Secretary
  • Dr. David McQuillan Ph.D.
    Chief Technical & Scientific Officer
  • Mr. Philip Scorgie
    Chief Information Officer
  • Mr. Ahmed Hassan
    Director of Operations
  • Ms. Teena Chadha
    APAC Marketing & Distributor Manager
  • Ms. Monica Benyk
    HR Manager
  • Dr. Tim Moore
    Principal Scientist
  • Mr. Edward Graubart
    Senior Vice President of Sales & Marketing (Americas)

PNV Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of PolyNovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PolyNovo investors own include Immutep (IMMP), Rural Funds Group (RFF), Vanguard FTSE Pacific ETF (VPL), UQM Technologies (UQM), Tesla (TSLA), Starpharma (SPL), Moelis Australia (MOE), iSignthis (ISX), Align Technology (ALGN) and Acasti Pharma (ACST).

This page (ASX:PNV) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners